LYL-119

N/A

Report date: 2022/11/18 11:12:58

Base Information

Drug NameLYL-119

Drug Alias NameLYL119LYL-119

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLyell Immunopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A